Couverture de VAT Trap

VAT Trap

VAT Trap

De : Dr Edward Leatham
Écouter gratuitement

À propos de ce contenu audio

 The VAT Trap book, blog and digital media series reveals how visceral fat — the hidden metabolic organ — drives heart disease, hypertension, and diabetes. Drawing on 30 years of frontline cardiology and the latest in imaging, app-based tracking, and metabolic science, Dr Ed Leatham translates complex research into clear, actionable steps. Whether you want to avoid heart disease, stabilise your metabolism, or understand GLP-1 therapy, these four concise podcast seasons accompany a four book series that will help you see, track, and reverse the VAT trap. To join the mailing list click on the link below and add your email https://link.scvc.co.uk/vat-trap-join-newsletterGreen Pages Publication Exercice et forme physique Fitness, alimentation et nutrition Hygiène et vie saine Maladie et pathologies physiques
Épisodes
  • Sarcopenia: Are We Diagnosing the Wrong Muscle Problem?

    Sarcopenia: Are We Diagnosing the Wrong Muscle Problem?
    Mar 25 2026

    In cardiometabolic medicine, muscle is not a cosmetic tissue but a metabolic organ. Evidence consistently shows that strength, not muscle mass, predicts insulin resistance, cardiovascular risk, and survival. Many older adults are not losing muscle tissue — they are losing muscle function, and that is the pathology that matters.

    Read Blog

    Afficher plus Afficher moins
    21 min
  • The Cardiometabolic Reset: Escaping the Metabolic Doom Loop

    The Cardiometabolic Reset: Escaping the Metabolic Doom Loop
    Mar 3 2026

    The Eight-Month Metabolic Reset is a structured cardiometabolic programme designed to reduce visceral fat, preserve skeletal muscle strength, and improve glucose stability. Combining lifestyle change, targeted metabolic support, and clinical guidance, it helps break the cardiometabolic cycle and build sustainable long-term health beyond short-term weight loss.

    Read the blog
    Afficher plus Afficher moins
    23 min
  • Prediabetes as a Therapeutic Target: A Cardiologist’s Editorial Perspective

    Prediabetes as a Therapeutic Target: A Cardiologist’s Editorial Perspective
    Feb 27 2026

    Prediabetes should be viewed as an active cardiometabolic disease stage rather than a passive risk marker. Cardiovascular injury begins before overt diabetes, creating a critical window for intervention. Lifestyle therapy remains fundamental, while agents such as metformin, GLP-1 receptor agonists, dual incretin therapies, and SGLT2 inhibitors may help modify long-term cardiovascular risk.

    https://www.scvc.co.uk/vat/glucose-insulin-dynamics/prediabetes-as-a-therapeutic-target-a-cardiologists-editorial-perspective/
    Afficher plus Afficher moins
    21 min
Aucun commentaire pour le moment